Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene

Blood

Volumn 104, Issue 9, 2004, Pages 2767-2774

  Sabatino, Denise E ^b   Armstrong, Elina ^b   Edmonson, Shyrie ^b   Liu, Yi Lin ^b   Pleimes, Marc ^b   Schuettrumpf, Joerg ^b   Fitzgerald, Julie ^b   Herzog, Roland W ^b   Arruda, Valder R ^b   High, Katherine A ^a  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; GENE PRODUCT; PREALBUMIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; FEMALE; GENE DELETION; GENE MUTATION; GENETIC TRANSFECTION; HEMOPHILIA B; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; MISSENSE MUTATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STOP CODON; TRANSGENE; TRANSGENIC MOUSE; WILD TYPE;

EID: 7244231207     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-03-1028     Document Type: Article

References (54)

1. Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene: a model for hemophilia A. Nature Genet. 1995;10:119-121.
2. Suh TT, Holmback K, Jensen NJ, et al. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice. Genes Dev. 1995;9:2020-2033.
3. High KA. Gene transfer as an approach to treating hemophilia. Circulation Research. 2001;88:137-144.
4. Walsh C. Gene therapy for hemophilia: are viral vectors really feasible? J Thromb Haemost. 2003;1:218-219.
5. Hrachovinova I, Cambien B, Hafezi-Moghadam A, et al. Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. Nat Med. 2003;9:1020-1025.
6. Kundu RK, Sangiorgi F, Wu LY, et al. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood. 1998;92:168-174.
7. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90:3962-3966.
8. Wang L, Zoppe M, Hackeng TM, Griffin JH, Lee KF, Verma IM. A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A. 1997;94:11563-11566.
9. Green PM, Montandon AJ, Ljung R, et al. Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counselling of diseases with high mutational heterogeneity. Br J Haematol. 1991;78:390-397.
10. Green PM, Montandon AJ, Bentley DR, Giannelli F. Genetics and molecular biology of haemophilias A and B. Blood Coag Fibrinol. 1991;2:539-565.
11. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med. 1993;328:453-459.
12. Wang W, Czaplinski K, Rao Y, Peltz SW. The role of Upf proteins in modulating the translation read-through of nonsense-containing transcripts. EMBO J. 2001;20:880-890.
13. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med. 2003;349:1433-1441.
14. Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature. 2003;426:905-909.
15. Yan C, Costa RH, Darnell JEJ, Chen JD, VanDyke TA. Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. EMBO J. 1990;9:869-878.
16. Kurachi S, Hitomi Y, Furukawa M, Kurachi K. Role of intron 1 in expression of the human factor IX gene. J Biol Chem. 1995;270:5276-5281.
17. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci U S A. 1989;86:10095-10099.
18. Hogan B, Constantini F, Lacy E. Manipulating the Mouse Embryo: A Laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1986.
19. Walter J, You Q, Hagstrom JN, Sands M, High KA. Successful expression of human factor IX following repeat administration of adenoviral vector in mice. Proc Natl Acad Sci U S A. 1996;93:3056-3061.
20. Fields PA, Arruda VR, Armstrong E, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther. 2001;4:201-210.
21. Herzog R, Hagstrom N, Kung S, et al. Stable gene transfer and expression of human FIX following intramuscular injection of recombinant AAV. Proc Natl Acad Sci U S A. 1997;94:5804-5809.
22. Kung SH, Hagstrom JN, Cass D, et al. Human factor IX corrects the bleeding diathesis of mice with hemophilia B. Blood. 1998;91:784-790.
23. Herzog RW, Yang E, Couto L, et al. Long-term correction of canine hemophilia B by AAV-mediated gene transfer of blood coagulation factor IX. Nature Med. 1999;5:56-63.
24. Fields PA, Kowalczyk DW, Arruda VR, et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther. 2000;1:225-235.
25. Green P. Haemophilia B mutation database: a database of point mutations and short additions and deletions in the factor IX gene (version 12). http://www.kcl.ac.uk/ip/petergreen/haemBdatabase.html. Accessed August 31, 2004.
26. Herzog RW, Arruda VR, Fisher TH, Read MS, Nichols TC, High KA. Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony. Thromb Haemost. 2000;84:352-354.
27. Huang MN, Kasper CK, Roberts HR, Stafford DW, High KA. Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg-Gln at the carboxy-terminal cleavage site of the activation peptide. Blood. 1989;73:718-721.
28. Watzke HH, Wallmark A, Hamaguchi N, Giardina P, Stafford DW, High KA. Factor XSanto Domingo: evidence that the severe clinical phenotype arises from a mutation blocking secretion. J Clin Invest. 1991;88:1685-1689.
29. Mauser AE, Whitlark J, Whitney KM, Lothrop CD Jr. A deletion mutation causes hemophilia B in Lhasa Apso dogs. Blood. 1996;88:3451-3455.
30. Maquat LE, Kinniburgh AJ, Rachmilewitz EA, Ross J. Unstable beta-globin mRNA in mRNA-deficient beta o thalassemia. Cell. 1981;27:543-553.
31. Forget BG, Benz EJ Jr, Skoultchi A, Bagiioni C, Housman D. Absence of messenger RNA for beta globin chain in beta(0) thalassaemia. Nature. 1974;247:379-381.
32. Benz EJ, Forget BG, Hillman DG, et al. Variability in the amount of beta-globin mRNA in beta0 thalassemia. Cell. 1978;14:299-312.
33. Arruda VR, Schuettrumpf J, Herzog RW, et al. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. Blood. 2004;103:85-92.
34. Giannelli F, Green PM, Sommer SS, et al. Haemophilia B: database of point mutations and short additions and deletions, 7th edition. Nucleic Acids Res. 1997;25:133-135.
35. Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatric Hematol Oncol. 1997;19:23-27.
36. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A. 1989;86:1382-1386.
37. Russell KE, Olsen EH, Raymer RA, et al. Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood. 2003;102:4393-4398.
38. White GC, Beebe A, Nielsen B. Recombinant factor IX. Thromb Haemost. 1997;78:261-265.
39. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16:270-276.
40. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using reeombinant adeno-associated viral vectors. Nat Med. 1999;5:64-70.
41. Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotype correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood. 2002;99:2670-2676.
42. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther. 2000;1:154-158.
43. Byers PH. Killing the messenger: new insights into nonsense-mediated mRNA decay. J Clin Invest. 2002;109:3-6.
44. Hougie C, Twomey JJ. Haemophilia Bm: a new type of factor-IX deficiency. Lancet. 1967;1:698-700.
45. Monrae DM, McCord DM, Huang MN, et al. Functional consequences of an arginine 180 to glutamine mutation in factor IX Hilo. Blood. 1989;73:1540-1544.
46. Herzog RW, Fields PA, Arruda VR, et al. Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy. Hum Gene Ther. 2002;13:1281-1291.
47. Arruda VR, Hagstrom JN, Deitch J, et al. Post-translational modifications of recombinant myotube-synthesized human factor IX. Blood. 2001;97:130-138.
48. Kaufman RJ, Wasley LC, Furie BC, Furie B, Shoemaker CB. Expression, purification and characterization of recombinant g-carboxylated factor IX synthesized in Chinese hamster ovary cells. J Biol Chem. 1996;261:9622-9628.
49. Jallat S, Perraud F, Dalemans W, et al. Characterization of recombinant human factor IX expressed in transgenic mice and in derived transimmortalized hepatic cell lines. EMBO J. 1990;9:3295-3301.
50. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet. 2001;10:291-299.
51. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996;2:467-469.
52. Barton-Davis E, Cordier L, Shorturma D, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscle of mdx mice. J Clin Invest. 1999;104:375-381.
53. Xu L, Gao C, Sands MS, et al. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood. 2003;101:3924-3932.
54. Yoshitake S, Schach BG, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (antihemophilic factor B). Biochemistry. 1985;24:3736-3750.